B cell depletion for autoimmune diseases in paediatric patients

Clinical Rheumatology

Volumn 30, Issue 1, 2011, Pages 87-97

  Jansson, Annette F ^a   Sengler, Claudia ^b   Kuemmerle Deschner, Jasmin ^c   Gruhn, Bernd ^d   Kranz, A Birgitta ^e   Lehmann, Hartwig ^f   Kleinert, Daniela ^g   Pape, Lars ^h   Girschick, Hermann J ^l   Foeldvari, Ivan ^m   Haffner, Dieter ^o   Haas, Johannes P ⁿ   Moebius, Dagmar ⁱ   Foell, Dirk ^k   Peitz, Joachim ^j   Grote, Veit ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g Kinderklinik   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ CARL THIEM KLINIKUM   (Germany)

^j Unikinderklinik   (Germany)

^k UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^l VIVANTES HOSPITAL   (Germany)

^m Hamburger Zentrum fur Kinder und Jugendrheumatologie   (Germany)

ⁿ German Center for Pediatric and Adolescent Rheumatology   (Germany)

^o ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

more..

Author keywords

Adolescent; Autoimmune diseases; Child; Dysgammaglobulinaemia; Rituximab; Treatment outcome

Indexed keywords

ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; STEROID;

ARTICLE; B LYMPHOCYTE; CARDIOPULMONARY INSUFFICIENCY; COHORT ANALYSIS; COUGHING; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; NAUSEA AND VOMITING; NEPHROLOGY; NEPHROTIC SYNDROME; PARESTHESIA; PEDIATRICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VASCULITIS; VERTIGO;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DYSGAMMAGLOBULINEMIA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; STEROIDS; TREATMENT OUTCOME;

EID: 79151477960     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1630-0     Document Type: Article

References (50)

1. PJ Mease 2008 B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application J Rheumatol 35 1245 1255 1:CAS:528:DC%2BD1cXpslajtro%3D 18609733
2. BD Cheson JP Leonard 2008 Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma N Engl J Med 359 613 626 1:CAS:528:DC%2BD1cXpt12qtbw%3D 10.1056/NEJMra0708875 18687642
3. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A (2007) Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev (4):CD003805
4. E Keystone P Emery CG Peterfy PP Tak S Cohen MC Genovese M Dougados GR Burmester M Greenwald TK Kvien S Williams D Hagerty MW Cravets T Shaw 2009 Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Ann Rheum Dis 68 216 221 1:CAS:528:DC%2BD1MXisVSjs7o%3D 10.1136/ard.2007.085787 18388156
5. LB Giulino JB Bussel EJ Neufeld 2007 Treatment with rituximab in benign and malignant hematologic disorders in children J Pediatr 150 338 344 10.1016/j.jpeds.2006.12.038 17382107
6. SL Hauser E Waubant DL Arnold T Vollmer J Antel RJ Fox A Bar-Or M Panzara N Sarkar S Agarwal A Langer-Gould CH Smith 2008 B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 676 688 1:CAS:528:DC%2BD1cXhvVehtb0%3D 10.1056/NEJMoa0706383 18272891
7. A Podolskaya M Stadermann C Pilkington SD Marks K Tullus 2008 B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus Arch Dis Child 93 401 406 1:STN:280:DC%2BD1c3msVCkuw%3D%3D 10.1136/adc.2007. 126276 18039744
8. O Nwobi CL Abitbol J Chandar W Seeherunvong G Zilleruelo 2008 Rituximab therapy for juvenile-onset systemic lupus erythematosus Pediatr Nephrol 23 413 419 10.1007/s00467-007-0694-9 18097688
9. WG Leen CM Weemaes MM Verbeek MA Willemsen JJ Rotteveel 2008 Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome Pediatr Neurol 39 213 217 10.1016/j.pediatrneurol. 2008.05.015 18725071
10. V Guigonis A Dallocchio V Baudouin M Dehennault C Hachon-Le Camus M Afanetti J Groothoff B Llanas P Niaudet H Nivet N Raynaud S Taque P Ronco F Bouissou 2008 Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases Pediatr Nephrol 23 1269 1279 10.1007/s00467-008-0814-1 18465150
11. L Titomanlio N Soyah V Guerin C Delanoe G Sterkers P Evrard I Husson 2007 Rituximab in subacute sclerosing panencephalitis Eur J Paediatr Neurol 11 43 45 10.1016/j.ejpn.2006.10.005 17140822
12. AJ Mamelak MP Eid BA Cohen GJ Anhalt 2007 Rituximab therapy in severe juvenile pemphigus vulgaris Cutis 80 335 340 18038698
13. M Franchini M Zaffanello D Veneri G Lippi 2007 Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors Pediatr Blood Cancer 49 6 10 10.1002/pbc.21166 17311349
14. MA Cooper DL Willingham DE Brown AR French FF Shih AJ White 2007 Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients Arthritis Rheum 56 3107 3111 1:CAS:528:DC%2BD2sXht1GgtbrN 10.1002/art.22856 17763414
15. AM Patel TJ Lehman 2008 Rituximab for severe refractory pediatric Wegener granulomatosis J Clin Rheumatol 14 278 280 10.1097/RHU.0b013e3181886064 18824926
16. E Kimby 2005 Tolerability and safety of rituximab (MabThera) Cancer Treat Rev 31 456 473 1:CAS:528:DC%2BD2MXhtFKnu7vJ 10.1016/j.ctrv.2005.05.007 16054760
17. AF Jansson U Wintergerst ED Renner BH Belohradsky 2007 Rituximab-induced long-term remission in two children with SLE Eur J Pediatr 166 177 181 10.1007/s00431-006-0217-x 16915375
18. V Guerin K Yakouben B Lescoeur B Pedron JH Dalle A Baruchel G Sterkers 2008 Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child Transplantation 86 1322 1323 10.1097/TP.0b013e318188ac0c 19005417
19. E Parodi B Nobili S Perrotta SM Rosaria Matarese G Russo M Licciardello M Zecca F Locatelli S Cesaro G Bisogno P Giordano D De Mattia U Ramenghia 2006 Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment Int J Hematol 84 48 53 1:CAS:528:DC%2BD28XovVSisb0%3D 10.1532/IJH97.E0518 16867902
20. SD Marks S Patey PA Brogan N Hasson C Pilkington P Woo K Tullus 2005 B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus Arthritis Rheum 52 3168 3174 1:CAS:528:DC%2BD2MXhtF2msrvN 10.1002/art.21351 16200620
21. CM Bennett ZR Rogers DD Kinnamon JB Bussel DH Mahoney TC Abshire H Sawaf TB Moore ML Loh BE Glader MC McCarthy BU Mueller TA Olson AN Lorenzana WC Mentzer GR Buchanan HA Feldman EJ Neufeld 2006 Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Blood 107 2639 2642 1:CAS:528:DC%2BD28XjtlKltbk%3D 10.1182/blood-2005-08-3518 16352811
22. M Willems E Haddad P Niaudet I Kone-Paut A Bensman P Cochat G Deschenes F Fakhouri T Leblanc B Llanas C Loirat P Pillet B Ranchin R Salomon T Ulinski B Bader-Meunier 2006 Rituximab therapy for childhood-onset systemic lupus erythematosus J Pediatr 148 623 627 1:CAS:528:DC%2BD28XltFGju7k%3D 10.1016/j.jpeds.2006.01.041 16737873
23. M El-Hallak BA Binstadt AM Leichtner CM Bennett EJ Neufeld RC Fuhlbrigge D Zurakowski RP Sundel 2007 Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases J Pediatr 150 376 382 1:CAS:528:DC%2BD2sXjsVequ7k%3D 10.1016/j.jpeds.2006.10.067 17382113
24. P Emery R Fleischmann A Filipowicz-Sosnowska J Schechtman L Szczepanski A Kavanaugh AJ Racewicz RF van Vollenhoven NF Li S Agarwal EW Hessey TM Shaw 2006 The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 54 1390 1400 1:CAS:528:DC%2BD28XlsFSquro%3D 10.1002/art.21778 16649186
25. Klein A, Cimaz R, Azoulay E, Baudouin V, Descloux E, Belot A, Hubert P, Quartier P, Decramer S, Niaudet P, Bader-Meunier B (2007) Early mortality in childhood onset systemic lupus erythematosus (SLE). Arthritis Rheum 56(Suppl.):S880
26. N Cooper DM Arnold 2010 The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases Br J Haematol 149 3 13 1:CAS:528:DC%2BC3cXltF2ltro%3D 10.1111/j.1365-2141.2010.08076. x 20151975
27. MA Stange O Tutarel S Pischke A Schneider CP Strassburg T Becker H Barg-Hock M Basturk K Wursthorn M Cornberg M Ott TF Greten MP Manns H Wedemeyer 2010 Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab Z Gastroenterol 48 258 263 1:STN:280: DC%2BC3c7gslGhsw%3D%3D 10.1055/s-0028-1109782 20127601
28. F Suzan M Ammor V Ribrag 2001 Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder N Engl J Med 345 1000 1:STN:280:DC%2BD3MrivVylsw%3D%3D 10.1056/NEJM200109273451315 11575282
29. A Bermudez F Marco E Conde E Mazo M Recio A Zubizarreta 2000 Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma Haematologica 85 894 895 1:STN:280:DC%2BD3M%2FksF2jsw%3D%3D 10942955
30. FDA (US Food and Drug Administration) (2009) Rituxan (rituximab)-PML. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm187791.htm. Accessed 1 December 2009
31. S Imashuku T Teramura A Morimoto M Naya H Kuroda 2004 Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease Bone Marrow Transplant 33 129 130 1:STN:280:DC%2BD2c%2FgslWjsQ%3D%3D 10.1038/sj.bmt.1704307 14647260
32. SH Lim WV Esler Y Zhang J Zhang PO Periman C Burris M Townsend 2008 B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period Leuk Lymphoma 49 152 153 10.1080/10428190701742506 18203024
33. M Nishio K Fujimoto S Yamamoto T Endo T Sakai M Obara K Kumano K Minauchi K Yamaguchi Y Takeda N Sato K Koizumi M Mukai T Koike 2006 Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma Eur J Haematol 77 226 232 1:CAS:528:DC%2BD28XhtVSku7jE 10.1111/j.1600-0609.2006.00693.x 16923109
34. AR Walker A Kleiner L Rich C Conners RI Fisher J Anolik JW Friedberg 2008 Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma Cancer Invest 26 431 433 10.1080/07357900701809068 18443965
35. RJ Looney R Srinivasan LH Calabrese 2008 The effects of rituximab on immunocompetency in patients with autoimmune disease Arthritis Rheum 58 5 14 1:CAS:528:DC%2BD1cXhslOjsLc%3D 10.1002/art.23171 18163518
36. P Quartier B Brethon P Philippet J Landman-Parker F Le Deist A Fischer 2001 Treatment of childhood autoimmune haemolytic anaemia with rituximab Lancet 358 1511 1513 1:CAS:528:DC%2BD3MXot1Ojtb4%3D 10.1016/S0140-6736(01)06573-4 11705566
37. JC Edwards G Cambridge MJ Leandro 2006 B cell depletion therapy in rheumatic disease Best Pract Res Clin Rheumatol 20 915 928 1:CAS:528: DC%2BD28Xps1Cnurk%3D 10.1016/j.berh.2006.05.010 16980214
38. E Keystone R Fleischmann P Emery DE Furst R van Vollenhoven J Bathon M Dougados A Baldassare G Ferraccioli A Chubick J Udell MW Cravets S Agarwal S Cooper F Magrini 2007 Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis Arthritis Rheum 56 3896 3908 1:CAS:528:DC%2BD1cXnt1Olsg%3D%3D 10.1002/art.23059 18050221
39. YK Teng EW Levarht M Hashemi IM Bajema RE Toes TW Huizinga JM van Laar 2007 Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment Arthritis Rheum 56 3909 3918 1:CAS:528: DC%2BD1cXnt1Olsw%3D%3D 10.1002/art.22967 18050222
40. N Cooper EG Davies AJ Thrasher 2009 Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin Br J Haematol 146 120 122 1:CAS:528:DC%2BD1MXptlWgtro%3D 10.1111/j.1365-2141.2009.07715.x 19438506
41. L Diwakar S Gorrie A Richter O Chapman P Dhillon F Al-Ghanmi S Noorani MT Krishna A Huissoon 2010 Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 63 275 277 10.1136/jcp.2009.068940 20203231
42. A Pestronk J Florence T Miller R Choksi MT Al-Lozi TD Levine 2003 Treatment of IgM antibody associated polyneuropathies using rituximab J Neurol Neurosurg Psychiatry 74 485 489 1:STN:280:DC%2BD3s7is1Sjtg%3D%3D 10.1136/jnnp.74.4.485 12640069
43. SP Treon LM Pilarski AR Belch A Kelliher FI Preffer Y Shima CS Mitsiades NS Mitsiades AJ Szczepek L Ellman D Harmon ML Grossbard KC Anderson 2002 CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications J Immunother 25 72 81 10.1097/00002371-200201000-00008 11924912
44. E Irie Y Shirota C Suzuki Y Tajima K Ishizawa J Kameoka H Harigae T Ishii 2010 Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis Int J Hematol 91 501 508 1:CAS:528:DC%2BC3cXkt1antLs%3D 10.1007/s12185-010-0528-6 20217285
45. R Eisenberg RJ Looney 2005 The therapeutic potential of anti-CD20 "what do B-cells do?" Clin Immunol 117 207 213 1:CAS:528: DC%2BD2MXhtlGlsr%2FJ 10.1016/j.clim.2005.08.006 16169773
46. M Nishio T Endo K Fujimoto S Yamamoto M Obara K Yamaguchi Y Takeda H Goto I Kasahara N Sato T Koike 2009 FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation Eur J Haematol 82 143 147 1:CAS:528:DC%2BD1MXisVKhurk%3D 10.1111/j.1600-0609.2008. 01174.x 19018870
47. TY Lu T Jonsdottir RF van Vollenhoven DA Isenberg 2008 Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases Ann Rheum Dis 67 1493 1494 10.1136/ard.2008.091124 18791057
48. S Leuci D Levine J Zhang A Razzaque Ahmed 2009 Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells G Ital Dermatol Venereol 144 379 409 1:STN:280:DC%2BD1Mnis1yitw%3D%3D 19755943
49. JT Merrill CM Neuwelt DJ Wallace JC Shanahan KM Latinis JC Oates TO Utset C Gordon DA Isenberg HJ Hsieh D Zhang PG Brunetta 2010 Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 62 222 233 1:CAS:528:DC%2BC3cXhtFGnurfP 10.1002/art.27233 20039413
50. MR Pranzatelli ED Tate SJ Verhulst SJ Bertolone D Bhatla M Granger J Lebowizc SK Lockhart JM Wiley 2010 Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome J Pediatr Hematol Oncol 32 e167 e172 1:CAS:528:DC%2BC3cXosFGisLw%3D 10.1097/MPH.0b013e3181cf0726 20606544